Prostate and other male cancers:
Indications for: LUPRON DEPOT-3 MONTH 22.5mg
Palliative treatment of advanced prostatic carcinoma.
Give as single IM inj into gluteal area, anterior thigh or deltoid; rotate inj sites. 22.5mg once every 3 months (12 weeks). Do not split doses.
LUPRON DEPOT-3 MONTH 22.5mg Warnings/Precautions:
Initial worsening of signs/symptoms (eg, bone pain, ureteral obstruction, spinal cord compression) may occur; monitor closely in metastatic vertebral lesions, urinary obstruction, hematuria. Monitor serum testosterone, PSA. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Increased risk of convulsions in patients with history of seizures, epilepsy, cerebrovascular disorder, CNS anomalies or tumors. Risk of QT prolongation in long-term androgen deprivation therapy, congenital long QT syndrome, electrolyte abnormalities (correct and monitor), or CHF; consider monitoring ECGs. Instruct patient on correct self administration. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
LUPRON DEPOT-3 MONTH 22.5mg Classification:
LUPRON DEPOT-3 MONTH 22.5mg Interactions:
Concomitant antiarrhythmics may prolong the QT interval. Risk of seizures with concomitant SSRIs, bupropion, others.
Hot flashes/sweats, pain, GI disorders, edema, respiratory disorder, urinary disorders, inj site reaction, joint disorders, testicular atrophy, asthenia, flu syndrome, headache, skin reaction, fatigue; tumor flare, hyperglycemia, convulsions, hypersensitivity.
Depot kit—1 (prefilled dual-chamber syringe w. supplies)